Standard curve of SARS-CoV-2 Nucleocapsid Protein LFA Assay.

The LFA assay is developed by using SARS-CoV-2 Nucleocapsid Antibody (N338), mAb, mouse(GenScript, A02135) and MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit(GenScript, A02136) as the capture and detection antibodies, respectively.

The combination shows good dose response of fluorescence intensity and concentrations of SARS-CoV-2 Nucleocapsid protein in LFA assay.

Nucleocapsid protein concentration was nicely correlated with fluorescence intensity.

Western Blot of wild-type and delta variant Nucleocapsid protein cell lysates with MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit (GenScript, A02136).

M: Protein Marker (GenScript, M00521)
Lane 1: 3 μg Wild-type N protein cell lysate
Lane 2: 3 μg Delta N protein cell lysate


Primary Antibody:
MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit (GenScript, A02136) 1 μg/ml

Secondary Antibody:
Goat Anti-Rabbit IgG-HRP (GenScript, Cat No. A00131)

BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit (GenScript, A02136) to SARS-CoV-2 Nucleocapsid protein of wild type and delta variant.

MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34) captured on Protein A sensors surface can bind wild-type or delta variant with dissociation constant (KD) of 2.25E-09M and 6.83E-10M.

BLI (Biolayer interferometry) binding affinity measurements of MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34), mAb, Rabbit (GenScript, A02136) to nucleocapsid protein of SARS-CoV-2 omicron variant.

MonoRab™ SARS-CoV-2 Nucleocapsid Antibody (N34) captured on Protein A sensors surface can bind omicron variant with dissociation constant (KD) of 6.73E-10M.